Dainippon Sumitomo To Conduct Trials Outside Japan
This article was originally published in PharmAsia News
Executive Summary
Japan's Dainippon Sumitomo Pharma became the latest drug maker to announce it would shift some of its clinical trials to other Asian nations. Dainippon said that among the drugs being developed for the Japanese market is its antipsychotic treatment lurasidone, which is to undergo Phase III tests in South Korea and Taiwan. The move was made possible after Japan's health ministry indicated it would acknowledge foreign trials if they include at least some Japanese patients. Dainippon said future trials abroad would be held in areas where the people are similar physically to Japanese. (Click here for more - a subscription may be required
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.